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Background/aim: With the increased experience in living donor liver transplantation (LDLT), it has been adopted for the treatment of
hepatocellular carcinoma (HCC), with emerging discussions of criteria beyond tumor size and number. In contrast to deceased donor
liver transplantation (DDLT), recipient selection for LDLT is not limited by organ allocation systems. We discuss herein the assessment,
criteria, and experience with liver transplantation (LT) in HCC cases at a high-volume LDLT center.
Material and methods: Between August 2006 and December 2017, 191 adult LT HCC recipients with at least one-year follow-up were
retrospectively analyzed.
Results: In 191 patients, one-, three- and five-year survival rates were 87.2%, 81.6%, and 76.2%, respectively, including early postoperative
mortality. In 174 patients with long-term follow-up, one-, three- and five-year disease-free survival rates were 91.6%, 87.7%, and 84.4%,
respectively. When multivariate analysis was utilized, tumor differentiation was the only factor which statistically affected survival (p
= 0.025).
Conclusion: LDLT allows us to push the limits forward and the question “Are the criteria always right?” is always on the table. We can
conclude that, with the advantage of LDLT, every HCC patient deserves a case-by-case basis discussion for LT under scientific literature
support. In borderline cases, tumor biopsy might help determine the decision for LT.
Key words : Hepatocellular carcinoma, living donor liver transplantation, criteria, outcomes

1.Introduction
Hepatocellular carcinoma (HCC) is the most common
primary liver cancer and remains an ongoing problem,
with incidence increasing worldwide. It is also well
known that HCC develops mainly in chronically
diseased livers, with low median survival rates if
no treatment is received [1–3]. There are various
modalities for curative and palliative treatment.
Surgical resection and interventional radiological
treatment are the options with successful outcomes
in limited cases due to underlying chronic liver
disease. During the last decades, liver transplantation
(LT) became a radical treatment for HCC in that it
can simultaneously treat intrahepatic metastasis as
well as multicentric carcinogenesis and diseased liver
[4–6].

During the last two decades, Milan Criteria (MC) has
been implemented worldwide for LT in cases of HCC,
and many organ sharing programs now use MC for organ
allocation. Starting with the University of California, San
Francisco (UCSF) criteria [7], over the past decade, the
search for new criteria and discussions of LT algorithms
for HCC became a hot topic in the field. With increased
experience in living donor transplantation (LDLT),
LDLT was adopted in the setting of HCC treatment
with new discussions about criteria beyond the size and
number of tumors. In contrast to deceased donor liver
transplantation (DDLT), recipient selection for LDLT is
not limited by organ allocation systems.
In this study, we discuss the criteria for LT in HCC
cases, sharing our experience and assessment of our
HCC cases as a high volume LDLT center.
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2. Material and methods
Between August 2006 and December 2017, 1,067 LTs
(890 LDLT, 177 DDLT) were performed in 1027 patients
(704 adult, 323 pediatric) at our center. Following
Institutional Review Board approval, patient data was
collected retrospectively in 208 HCC LT patients. Pediatric
patients (<18 years), patients with other liver malignancies
combined with HCC, and patients lost to follow-up were
excluded. A total of 191 adult LT HCC recipients with
a minimum one-year follow-up were retrospectively
analyzed. Demographics, underlying liver disease, tumor
related radiological (total tumor size, total number of
tumors, largest tumor size) and pathological data (macroand microvascular invasion, tumor differentiation), AFP
levels, recurrence and survival rates) were recorded and
analyzed. In addition, patients were classified according
to MC and USCF criteria. SPSS version 13.0 (SPSS, Inc.,
Chicago, IL, USA) was used for the Kaplan Meier Survival
and Cox Regression Multivariate analysis.
2.1. Patient evaluation and selection
Starting from the beginning of the transplant program, all
chronic liver disease patients with HCC were evaluated
in the multidisciplinary selection meeting as possible LT
candidates. Beyond tumor size and number, patients who
did not have findings of extrahepatic or macrovascular
invasion, tumor thrombosis, lymphatic node or findings of
extrahepatic metastasis were evaluated as LT candidates.
During the evaluation and selection process, cases within
MC were approved both for DDLT and LDLT. Patients
were listed for DDLT according to the Turkish Health
Ministry organ allocation system rules and were asked
about potential related living liver donors. Cases beyond
MC were evaluated for LDLT according to their additional
findings. During this evaluation, beyond the tumor size
and number, we focused on findings which could give us
an idea about the biological behavior of the tumor. Tumor
growth rate and time, AFP level, tumor margin findings
at computed tomography (CT) or magnetic resonance
imaging (MRI) views, positron emission tomography
and computed tomography (PET-CT) findings,
response to other previous treatments, histopathological
differentiation (if there was a biopsy) and age of the
patients were the parameters, which we interpreted before
making a decision. One or two parameters supporting
poor biological behavior were not enough to make a
decision against LT. If most of the findings supported poor
biological behavior, alternative and bridging therapies
(transarterial chemoembolization - TACE, transarterial
radioembolization –TARE, and external beam radiation)
options were preferred instead of LT. In addition, all the
possibilities and risks were discussed at length with the
recipient, living donor candidate and family members.
Our living donor selection criteria and outcomes were
previously published [8].
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2.2.Immunosuppression
The protocol for immunosuppressive therapy was
triple maintenance immunosuppressive therapy at the
beginning, with a lower dose consisting of prednisone,
tacrolimus (Prograf, Astellas USA, Deerfield, IL), and
mycophenolate mofetil (Cell-Cept, Roche Laboratories,
Nutley, NJ). Prednisolone was stopped in all cases with
a taper at one month after transplant, and MMF was
stopped in most cases at three months after transplant.
Most patients with low tacrolimus levels (4–6 ng/mL)
were followed postoperatively according to their clinical
findings. In some HCC recurrence cases, mTor inhibitor
was started according to the decision made together with
the oncologist and hepatologist.
2.3.Follow-up after LT
A thoraco-abdominal CT or/and MRI were performed
every 3 months for the first year of follow-up, every 6
months between 1 and 3 years, and annually after 3 years.
AFP and clinical examination were performed every
month during the first 6 months and every 2 months
between 6 months and 1 year of follow-up, every 3 months
between 1 and 3 years, and every 6 months between 3
and 5 years. After 5 years, CT or MRI with AFP test was
performed annually or if clinically indicated. A biopsy of
all suspicious lesions was performed for recurrence, and
we attempted to treat all recurrent lesions with surgical
resection or interventional radiological treatment after the
determination of recurrence.
3. Results
Of the 191 cases, the mean age was 56.2 years (18–74
years), and 81.7% (n = 156) of patients were male. Only
14.1% (n = 27) were older than 65 years of age. The main
primary liver disease was chronic hepatitis B infection
(61.8%), followed by chronic hepatitis C infection (19.4%).
Most (66%) LT was performed from a living related liver
donor. Mean physiological model for end-stage liver
disease (MELD) score was 12.8 (6–29). Mean alpha
fetoprotein (AFP) level was 904 ng/mL (1–100,000 ng/
mL), but the median AFP level was 10.8ng/mL. According
to the preoperative radiological findings and evaluation,
115 (60%) of the 191 pathologically HCC approved cases
were within the MC (rMC), 45 (24.6%) were beyond the
MC (rMC), and 31 (16.2%) were incidentally discovered
HCC (iHCC) cases upon histopathological examination.
After histopathological examination, 120 (62.8%) cases
within the MC (pMC) and 71 (37.2%) were beyond the
MC (pMC). In addition, 54 (28.3%) of the all cases were
beyond the USCF criteria (Table 1).
Early postoperative mortality (first 6 months)
occurred due to sepsis, primary nonfunction (PNF),
multiorgan failure (MOF), cardiac arrest, and neurological
complications in 17 (8.9%) cases. These cases were included
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Table 1. Demographics.
Within pMC
n = 120

Beyond pMC
n = 71

Within USCF
n = 137

Beyond USCF
n = 54

Total
n = 191

56.5

56.0

56.4

55.9

56.2

Female

20.0 % (24)

15.5 % (11)

17.5 % (24)

20.4 % (11)

18.3% (35)

Male

80.0 % (96)

84.5 % (60)

82.5 % (113)

79.6 % (43)

81.7% (156)

Mean MELD Score

13.1

12.1

12.8

12.7

12.8

Mean AFP (ng/mL)

218

2064

197

2697

904

Median AFP (ng/mL)

6

22

5.9

27.4

8

HBV & HCV

84.2 % (101)

77.5 % (55)

83.9 % (115)

75.9 % (41)

81.7 % (156)

Others

15.8 % (19)

22.5 % (16)

16.1 % (22)

24.1 % (13)

18.3 % (35)

Early mortality ( %, n)

9.2 % (11)

8.5 % (6)

8.0 % (11)

11.1 % (6)

8.9 % (17)

Mean Age (years)
Sex ( %, n )

Primary Liver Disease

AFP: alpha-fetoprotein, MELD : the model for end-stage liver disease, HBV: chronic hepatitis B virus, HCV: chronic hepatitis
C virus, USCF: University of California, San Francisco criteria, pMC: pathological Milan criteria.

in the analysis. Of the 17 cases, 9 were within in the pMC
and 8 were beyond the pMC (4 of them were beyond the
USCF criteria). In addition, 8 were transplanted from a
deceased donor, and 9 were transplanted from a living
donor.
Of the 191 patients, there were 26 (13.6%) with
recurrent disease. Overall mortality was 20,9% (40/191).
When early mortalities (n = 17) are excluded, the adjusted
long-term mortality dropped to 13.2% (23/174) in HCC
recipients with at least one year of follow-up. In 174 patients
with long-term follow-up, 1-, 3- and 5-year disease-free
survival rates were 91.6%, 87.7%, and 84.4%, respectively.
With the inclusion of early postoperative mortalities,
1-, 3- and 5-year survival rates were 87.2%, 81.6%, and
76.2%, respectively. In 115 patients within rMC, 1-, 3and 5-year survival rates were 87.6%, 84.3%, and 79.1%,
respectively. In 45 patients beyond the rMC, 1-, 3- and
5-year survival rates were 84.2%, 73.7%, and 63.2%,
respectively. In 31 iHCC patients, 1-, 3- and 5-year survival
rates were 90.3%, 83.4%, and 83.4%, respectively. In 120
within pMC patients, 1-, 3- and 5-year survival rates were
89.1%, 85.2%, and 80.6%, respectively; and in 71 beyond
the pMC patients, 1-, 3- and 5-year survival rates were
84.1%, 76.02%, and 69.4%, respectively. There were no
differences between the within versus beyond the rMC (p
= 0.18) and within versus beyond pMC (p = 0.12). When
data were analyzed according to the pathological UCSF
criteria, in 137 within USCF patients, 1-, 3- and 5-year
survival rates were 89.5 %, 85.4%, and 81.2%, respectively,
and, in 54 beyond the UCSF patients 1-, 3- and 5-year
survival rates were 81.3%, 72.5%, and 64.5%, respectively.
There were statistical survival differences between within

UCSF patients versus beyond the UCSF patients (p =
0.029) (Table 2).
When the data were analyzed according to total tumor
numbers (1, 2, 3, 4-9 and more than 10 tumors), there was
not a significant difference between the five groups (p =
0.54) (Figure 1A). There were 13 cases with long-term
follow-up with more than 10 tumors; 3 deaths occurred
due to HCC recurrence in a total 6 cases with recurrence
(Table 3). We also instituted a cut-off for total tumor
size of 8 cm, as this was the most supported limit [9] in
the literature, and there were not significant differences
between total tumor size over and below 8 cm (p = 0.19)
(Table 2). With our evaluation system, we had a chance
to transplant only seven patients with the largest tumor
size more than 8 cm. Statistically, our case number was not
large enough to make a conclusion, but 5 lived for more
than 5 years and 3 are still living without HCC recurrence
more than 5 years posttransplant (Table 4). We did not
find any significant differences in our patient population
with AFP levels higher and lower than 200ng/mL (p =
0.89) (Table 2). There were only 16 cases followed longterm with AFP ≥400 ng/mL, and two deaths occurred due
to HCC recurrence in a total of 6 cases with recurrence
(Table 5). In our HCC patients, MELD scores of the
recipients did not affect survival rates by subgroup (p =
0.72). According to our univariate analysis, poor tumor
differentiation (p = 0.0001) (Figure 1B), microvascular
invasion (p = 0.004)(Table 2) and recipient age ≥65 (p
= 0.016) (Table 2) affected patient survival. Comparably
with all our LT patients, older HCC (age ≥65) recipient
survival rates at 1, 3 and 5 years (72.0%, 64.7% and 58.8%,
respectively) were significantly lower than those for
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Table 2. Kaplan–Meier survival comparison between subgroups.
First group (n) - 1, 3 and
5 year Survival Rates

Second group (n) 1, 3 and
5 year Survival Rates

p Value

Radiological

Within rMC (n = 115)

Beyond rMC (n = 45)

0.18

Milan Criteria(rMC)

1 year

87.6%

1 year

84.2%

3 year

84.3%

3 year

73.7%

5 year

79.1%

5 year

63.2%

Pathological

Within pMC (n = 120)

Beyond pMC (n = 71)

Milan Criteria(pMC)

1 year

89.1%

1 year

84.2%

3 year

85.2%

3 year

76.0%

5 year

80.6%

5 year

69.4%

USCF Criteria

AFP Level

Within USCF (n = 137)

Beyond USCF (n = 54)

1 year

89.5%

1 year

81.3%

3 year

85.4%

3 year

72.5%

5 year

81.2%

5 year

64.5%

AFP < 200 ng/mL (n = 165)

AFP ≥ 200 ng/mL (n = 26)

1 year

87.6%

1 year

84.6%

3 year

81.7%

3 year

80.8%

5 year

76.2%

5 year

75.7%

Total Tumor Size

tTs < 8 cm (n = 150)

tTs ≥ 8 cm (n = 41)

(tTs)

1 year

87.8%

1 year

88.7%

3 year

83.1%

3 year

83.1%

5 year

79.2%

5 year

69.8%

Recipient Age

Age < 65 ( n = 164 )

Age ≥ 65 (n = 27)

1 year

89.5%

1 year

72.0%

3 year

84.4%

3 year

64.7%

5 year

79.1%

5 year

58.8%

Microvascular

MVI (-) (n = 120)

MVI (+) (n = 68)

Invasion (MVI)

1 year

90.8%

1 year

80.4%

3 year

86.8%

3 year

71.8%

5 year

84.0%

5 year

61.6%

0.12

0.029

0.89

0.19

0.016

0.004

AFP: alpha-fetoprotein, MELD : the model for end-stage liver disease, USCF: University of California, San
Francisco criteria.

younger recipients (age <65) survival rates (89.5%, 84.4%
and 79.1%, respectively) (Table 2). When Cox regression
multivariate analysis was performed, including all the
factors, tumor differentiation was the only factor, which
statistically affected survival in our patients (p = 0.025)
(Table 6). Although our case number was not large enough
to reach statistical significance, largest tumor size greater
than 8 cm increased the overall HCC recurrence rate
(57.1%, n:4/7) and decreased the long-term overall patient
survival rate (71.4%, n:5/7) (Table 4).
In our HCC patients with recurrence, 1-, 3- and 5-year
survival rates were 81.3%, 54.7%, and 25.0%, respectively
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(Figure 2A). Of the 50 beyond UCSF patients with longterm follow-up for well-differentiated tumors (n = 10),
1-, 3- and 5-year survival rates were all 90% and, for
moderately differentiated tumors (n = 32), 1-, 3- and 5-year
survival rates were 84.1%, 76.7%, and 67.3%, respectively.
In this group, for poorly differentiated tumors (n = 8),
survival rates dropped to 46.0% at 1 year and 31.3% at 2
years (Figure 2B).
4. Discussion
It is agreed in the literature that one of the most important
steps for successful outcomes after LT in HCC is patient
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Survival Functions
Tumor Number

1.0

1
2
3
4-9
>=10
1-censored
2-censored
3-censored
4-9-censored
>=10-censored

Cum Survival

0.8

0.6

0.4

0.2

0.0
0

2

4

6

8

10

12

Survival Year

Figure 1A: Survival comparison with Kaplan–Meier between the 5 groups of number of tumors (1,2,3,4–9 and more
than 10).

Survival Functions
Differentiation

1.0

well
moderate
poor
well-censored
moderate-censored
poor-censored

Cum Survival

0.8

0.6

0.4

0.2

0.0
0

2

4

6

8

10

12

Survival Year

Figure 1B: Survival comparison with Kaplan–Meier between the 3 groups of tumor differentiation (well, moderate and poor).
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Table 3. Transplant patients followed long term with tumor number ≥10.
Tm
Number

Age

Tm
Diff.

AFP
(ng/mL)

Biggest
Tm size

Rec

Rec.time
(month)

Status

Post LT Year

1

>10

18

M

100000

7.0

Yes

14

Dead

3.1

2

>10

56

W

180

11.5

No

-

Alive

11.8

3

>10

54

M

234

6.0

No

-

Alive

9.6

4

>10

47

M

5

4.5

No

-

Alive

8.5

5

>10

61

M

3

2.8

Yes

11

Dead

2.6

6

>10

68

M

137

8.0

Yes

55

Alive

7.6

7

>10

29

M

341

2.5

Yes

35

Alive

7.2

8

>10

53

W

6

3.0

No

-

Alive

6.7

9

>10

62

M

6

10.0

Yes

36

Dead

3.2

10

>10

65

M

1426

3.5

No

-

Alive

6.7

11

>10

19

W

727

0.2

No

-

Alive

6.8

12

>10

61

M

7175

3.5

Yes

11

Alive

3.3

13

>10

59

M

2

3.7

No

-

Alive

1.8

AFP: alpha-fetoprotein, Tm:tumor, Diff: differentiation, Rec: recurrence, LT: liver transplant, W: well differentiated
tumors M; moderately differentiated tumors.
Table 4. Transplant patients followed long term with largest tumor ≥7 cm.
Largest
Tm size

Age

Tm
Diff.

AFP
(ng/mL)

Tm
Number

Rec

Rec.time
(month)

Status

Post LT Year

1

11.5

37

M

12520

1

No

-

Alive

9.1

2

10.0

62

W

6

>10

Yes

36

Death

3.2

3

10.0

51

M

1

7

Yes

4

Death

2.5

4

8.7

51

M

7447

1

Yes

9

Alive

5.6

5

8.0

55

M

1779

1

No

-

Alive

8.8

6

8.0

68

M

137

>10

Yes

55

Alive

7.6

7

8.0

57

W

15

1

No

-

Alive

8.8

8

7.2

60

P

9946

3.0

No

-

Alive

3.7

9

7.0

56

W

180

>10

No

-

Alive

11.8

10

7.0

51

M

6

1

Yes

6

Death

1.3

11

7.0

68

M

2

2

No

-

Alive

9.9

AFP: alpha-fetoprotein, Tm:tumor, Diff: differentiation, Rec:recurrence, LT:liver transplant, W: well differentiated
tumors, M:moderately differentiated tumors, P:poorly differentiated tumors

selection, as is true in many other areas of medicine [10].
With the improvements in LT, Mazzaferro et al. reported
MC for LT in HCC cases in 1996. In this report, survival
rates after LT for HCC cases were similar to the survival
rates after LT for other diseases [11]. Improved survival
rates in patients beyond MC on explant histopathology
started the discussion of extending patient selection criteria
for LT, as the aforementioned criteria were considered too
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restrictive. Starting with UCSF [7], many centers began
reporting excellent survival rates with their own new
criteria [12–25]. LDLT allows many centers to develop
center-specific expanded criteria with acceptable results
without consideration of allocation system limitations, and
LDLT in the setting of HCC has been adopted worldwide
over the past decade [9,10,26]. Sugawara et al. utilized a
5-5 rule (up to five nodules with a maximum diameter of
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Table 5. Transplant patients followed long term with AFP level ≥400 mg/mL.
No

AFP
(ng/mL)

Age

Tm
Diff.

Criteria

Tm
Number

Largest
Tm size

Rec

Rec. time
(month)

Status

Post LT Year

1

100000

18

M

B USCF

>10

5.0

Yes

14

Death

3.1

2

12520

37

M

B USCF

1

11.5

No

-

Alive

9.1

3

9946

60

P

B USCF

1

7.2

No

-

Alive

3.7

4

7447

51

M

B USCF

1

8.7

Yes

9

Alive

5.6

5

7325

55

M

MC

1

4.5

No

-

Alive

10.7

6

7175

61

M

B USCF

>10

3.5

Yes

11

Alive

3.3

7

3893

62

M

MC

1

3.5

No

-

Alive

3.1

8

2072

66

P

MC

1

3.3

Yes

4

Death

0.7

9

1799

55

M

B USCF

1

8.0

No

-

Alive

8.8

10

1426

65

M

B USCF

>10

3.5

No

-

Alive

6.7

11

1358

55

M

MC

1

4.0

Yes

72

Alive

12.0

12

1000

64

M

B USCF

2

5.0

No

-

Alive

5.1

13

727

19

W

B USCF

>10

0.2

No

-

Alive

6.8

14

721

65

P

B USCF

4

2.9

No

-

Alive

4.2

15

551

69

M

MC

1

4.5

Yes

13

Alive

2.9

16

497

66

M

USCF

2

3.8

No

Alive

7.9

AFP: alpha-fetoprotein, Tm: tumor, Rec: recurrence, LT: liver transplant, MC: Within Milan criteria, B USCF: Beyond The University
of California, San Francisco criteria, USCF: Within The University of California, San Francisco criteria, Diff: differentiation W: well
differentiated tumors, M: moderately differentiated tumors, P: poorly differentiated tumors.
Table 6. Cox-regression multivariate analysis.
B

SE

Wald

df

P Value (Sig)

Exp(B)

rMC

0.066

0.372

0.031

1

0.859

1.068

pMC

0.913

0.771

1.403

1

0.236

2.469

USCF

–0.993

0.718

1.911

1

0.167

0.371

AFP Level (200ng/mL)

–0.594

0.485

1.503

1

0.220

0.552

Tm differentiation

0.800

0.357

5.009

1

0.025

2.225

Microvascular invasion

0.461

0.371

1.537

1

0.215

1.585

Tm number

–0.100

0.178

0.318

1

0.573

0.905

Total tm size (8 cm)

0.083

0.530

0.025

1

0.875

1.087

Recipient MELD score

0.163

0.151

1.155

1

0.282

1.177

Recipient age (65)

0.476

0.390

1.489

1

0.222

1.609

AFP: alpha-fetoprotein, MELD: the model for end-stage liver disease, USCF: University of California, San
Francisco criteria, Tm: tumor, rMC: radiological Milan criteria, pMC: pathological Milan criteria.

5 cm), and reported a 3-year recurrence-free survival rate
of 94% after LDLT [27]. With new limits, Mazzaferro et
al. proposed even more liberal criteria than MC: up-to-7
criteria (up to 7 tumors, with the size of the largest tumor
up to 7 cm ). They reported that beyond the MC but within
up-to-7 criteria in the absence of microvascular invasion

had a similar survival rate compared with patients within
MC, irrespective of microvascular invasion [28]. Lee et al.
reported that beyond the MC with PET-negative status
and a total tumor size <10 cm showed similar overall
survival and disease-free survival compared to within
MC recipients [29]. With the advantage of LDLT, at many
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Figure 2A: Survival comparison with Kaplan–Meier between the tumor recurrence and nonrecurrence groups.
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Figure 2B: Survival comparison with Kaplan–Meier between the 3 groups of tumor differentiation in beyond the USCF patients
(well, moderate and poor).
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centers, especially in Asia, patients with advanced HCC
are considered on a case-by-case basis, and risks factors
for recurrence, chance of survival, and strong wishes of
the patient, donor, and her/his family are considered [30].
However, the selection criteria are still a matter of debate.
Under the influence of ongoing discussions in the
literature, starting with the first case we evaluated, all
chronic liver disease patients with HCC were considered
case-by-case in our multidisciplinary selection meeting.
With the advantage of LDLT, we did not limit our
discussions around any criteria. Beyond the tumor size
and number, if the patients did not have findings of
extrahepatic or macrovascular invasion, tumor thrombosis,
lymphatic node or extrahepatic metastasis findings, they
were evaluated as an LT candidate. In contrast to DDLT,
the indications for LDLT for HCC were decided based on
the balance between risks to the living donor and benefits
to the recipient [4]. We considered all findings, which
provide hints about the biological behavior of the tumor.
Tumor growth rate in time, AFP level, tumor margin
findings at computed tomography (CT) or magnetic
resonance imaging (MRI) views, 18F-labeled fluoro-2deoxyglucose positron emission tomography (18F-FDG
PET) findings, response to other previous treatments,
histopathological differentiation (if there was a biopsy)
and age of the patients were the parameters we interpreted
before making the decision. Only one or two parameters
supporting poor biological behavior were not enough to
make the decision against LT. The more the morphological
limits of selection criteria expand, the more the recurrence
rates after LT increase [4]. If most of the findings supported
poor biological behavior, alternative and bridge treatment
options were suggested instead of LT. In addition, all the
possibilities and risks were discussed at length with the
recipient, donor candidate and family members. With
this evaluation, our survival rates are comparable with the
literature and are acceptable.
According to our analysis, which is also supported
widely by the literature, tumor differentiation is the most
important factor affecting survival rates. However, biopsy
for patients with a decompensated cirrhotic liver is not
always possible due to retention of ascites and risk of
bleeding as well as tumor dissemination. It could help us
to know the tumor differentiation before the decision, but
a biopsy cannot accurately diagnose the most advanced
degree of differentiation due to the heterogeneity of
HCC tumors [4]. Preoperative tumor biopsy and grading
analysis have huge variability in specificity and sensitivity,
which poses limitations for the prognostic value of biopsy
[31]. There is a seeding risk of 3%, false negative rate of
30%, and only 12.5% sensitivity for the identification of
microvascular invasion [32,33]. In contrast, the Toronto
group reported that the preoperative biopsy is 90%

effective in excluding patients with a poorly differentiated
lesion. Their recurrence rate related to the preoperative
biopsy was 1.9%, which was consistent with previous
studies. The Toronto group also reported the biopsy results
as one of the main criteria [20]. Dubay et al. reported the
usefulness of pretransplant liver biopsy and proposed that
LT for advanced moderate to well-differentiated HCC
can be performed safely with excellent 5-year overall and
disease‑free survival in the absence of size and tumor
number restrictions [34]. In our previous short review of
our experience correlated to a meeting, we concluded that,
considering tumor differentiation, a preoperative biopsy
can help select the best HCC patients for transplant even
beyond the UCSF criteria with reasonable outcomes [35],
but we did not perform routine biopsies in our patients
due to the concerns in the literature. Centers’ experiences
differ in regard to preoperative tumor biopsy.
Therefore, noninvasive methods, including tumor
markers, CT findings and PET are desirable for predicting
the tumor biology. In addition, bridging therapies
(transarterial chemoembolization - TACE, transarterial
radioembolization -TARE and external beam radiation)
prior to LT help control local disease progression [36].
Moreover, imaging modalities have dramatically improved
in the last two decades. Some radiologic imaging findings,
such as large tumor diameter, tumor margins, the presence
of tumor capsule, the distance from tumor to liver capsule,
tumor internal homogeneity, contrast enhancement
patterns on postcontrast dynamic and hepatobiliary phase
images, and diffusion restriction on diffusion weighted
images can predict microvascular invasion (MVI). In
addition, some clue imaging findings, especially beak and
bulging signs, may predict MVI, allowing the clinician to
biopsy [37]. We routinely used these noninvasive methods
during our evaluation. In some borderline cases, we
performed a biopsy for the final decision.
Many earlier studies have shown the importance of
vascular invasion as a prognostic marker. Pommergaard
HC et al. reported that patients without vascular invasion,
regardless of size and number of nodules, had a survival
comparable to MC and up-to-7 criteria [32]. On the
basis of the idea that incorporating tumor biological
markers and predicting microvascular invasion and poor
differentiation can exclude patients with a high risk of
recurrence before LT, some expanded criteria that include
such markers have recently been proposed [20,38,39]. Our
data also support these reports in the literature.
Piardi T. et al reported that tumor size more than 8 cm,
AFP level and histologic grading were only independent
significant prognostic factors in their LT patients for HCC
[31]. With our evaluation system looking at many factors
related to poor outcome, we did a limited number of cases
with the largest tumor more than 8 cm. In our limited
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number of cases with the largest tumor size over 8 cm, our
data support this literature, with the exception of AFP level.
Our experience showed that with the increase in the largest
tumor size, other additional poor prognostic factors were
seen more often. In addition, when we reviewed our data
case by case, an important number of our patients with
more than 10 tumors (n = 13) and the largest tumor size
greater than 7 cm (n = 11) who underwent LT and were
followed long term had the opportunity to live more than
5 years instead of losing their lives much earlier (Table 3
and 4).
Pre-transplant AFP is independently associated with
post‑transplant HCC recurrence survival, suggesting that
elevated levels reflect increased tumor aggressiveness that
is present even with recurrent disease [40–41]. Elevated
AFP is an important prognostic marker associated with
the presence of microvascular invasion and poor tumor
differentiation [42]. Hong et al. reported that serum AFP
levels and 18F-FDG PET positivity represent [43], in place
of morphological factors, new biological criteria that can
improve the risk stratification of tumor recurrence more
than the MC for LDLT recipients with HCC [43–44].
Although AFP is the most widely used tumor marker for
HCC, only half of all tumors secrete this protein. Thus, AFP
may not be an optimal indicator of risk [2]. According
to our data, AFP could not be the only marker associated
with the poor outcomes. When we looked case by case at
our 16 HCC patients with AFP levels higher than 400 mg/
mL, remarkably, 14 of them were still alive years after LT
(Table 5).
Many new prognostic biomarkers were studied in
the literature to establish the outcomes of HCC patients
undergoing LT. The most examined biomarker is the
serum AFP level. In addition, an association has been
found between increased HCC recurrence and high serum
levels of Des-gamma –carboxy prothorombin, E-cadherin,
beta-catenin and high HCC expression of GPC-3, but
additional research is necessary to establish the prognostic
role these biomarkers [45].
Most of the findings in literature supported that poor
biological behavior is the most important impact factor for
the outcome. Tumor differentiation is the well-establihed
one, which is also supported widely by the literature
findings. According to our analysis, tumor differentiation
is the only factor that impacts the outcome, which can
be a conflict with some of the literature findings such as
AFP level, tumor size, 18F-FDG PET, other bimarkers
etc. With our evaluation system, we might had a chance
to transplant limited number of patients to analyze some
of these factors, which might also impact the outcome.
This is one of the limitations in our analysis to make a
better conclusion. However, we strongly consider a caseby-case basis evaluation for the LT in HCC cases with a
multidisciplinary team.
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Some studies have suggested that immunosuppression
with the mammalian targets of rapamycin (mTOR)
inhibitor, such as everolimus or sirolimus, may reduce
the risk of HCC recurrence after LT [46]. We followed
most of our cases with low tacrolimus levels and switched
tacrolimus to mTOR inhibitors in limited recurrence cases.
We always tried to treat the recurrent lesions with surgical
or interventional radiological treatment. Our experience is
limited with mTOR inhibitors for statistical analysis.
Although overall outcomes are better after LDLT for
treatment of HCC, some previous studies had reported
that LDLT HCC recipients had worse recurrence compared
to DDLT HCC recipients. This was postulated to be due
to the lack of ability to test the tumor biology during
the waitlist time, which is shorter for LDLT recipients
[21,30,47]. Hypotheses include fast-tracking patients to
LT, growth factor and cytokines released during the rapid
regeneration of a partial graft, surgery technique (may be
no-touch total hepatectomy technique). Since LD grafts
are not public resources, it is already accepted in the LT
community that the recurrence risk of HCC, survival
benefit of the recipient, and wishes of the donor should
be considered for LDLT candidate selection [30]. In
addition, experience with successful LDLT after intensive
multidisciplinary treatment for HCC patients with
portal vein tumor thrombus, which has been accepted
as a contraindication even in the LDLT setting, has been
reported in the literature [48–50].
Our endorsement for LDLT would only make sense if
we can provide a safe donation environment with a low
complication profile. Many centers from Turkey reported
their living liver donation complication rates [51–54].
We previously reported complications and outcomes of
our 890 living donor hepatectomy cases [8]. No death is
reported in our series. Greater experience and knowledge
of LDLT will allow reduced donor morbidity.
Both the European Association for Study of the Liver
(EASL) and American Association for Study of the Liver
Disease (AASLD) recently revised guidelines to continue to
recommend MC as the benchmark for selection and argue
that there is a lack of uniform consensus and limitations
inherent to retrospective analysis [55–56]. Literature and
guidelines strongly encourage centers moving away from
MC to carefully collect prospective data on outcomes
using new criteria for selecting patients [57].
5. Conclusion
We know that criteria for any medical treatment is
important and is usually mandatory. Our data statistically
showed that USCF criteria seems more reasonable
according to MC. The literature supports LDLT and
allows us to push the limits forward. The question “Are the
criteria always right?” is always on the table. According
to our experience and with the support of the literature,

YANKOL et al. / Turk J Med Sci
we can conclude that, with the advantage of LDLT, all
HCC patients deserve a case-by-case basis discussion for
LT under the scientific literature support. In borderline
cases, tumor biopsy might help to make a decision about
whether to perform LT.
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